Developer of OneTest which is a blood test and machine learning algorithm combined to aid in the detection of multiple cancers including pancreatic, colon, lung, kidney, ovarian and bladder cancer. Acuresis Bio, South Korea Provider of a pancreatic cancer diagnostic kit. This company is currently operating in stealth mode. Beken Bio, USA Developer of liquid biopsy-based cancer detection utilizing cancer-specific antigens transported by extracellular vesicles and a machine learning AI based algorithm. Their laboratory developed test is called 3DReveal which is under clinical validation for the early detection of ovarian cancer, with expansion into lung, pancreatic, and colorectal cancers within the next 18 months 192 (C. M., personal communication, Oct 17, 2023) BRAHMS/ Thermo Fisher Scientific BRAHMS is a part of Thermo Fisher Scientific. Their CgA II KRYPTOR test is used for the early identification of gastroentero-pancreatic neuroendocrine tumors. It is the first FDA-cleared, automated immunofluorescent assay for the quantitative determination of the concentration of chromogranin A in human serum. Burning Rock Dx, USA Developer of the OverC Multi-Cancer Detection Blood Test that tests for 5 cancer types including liver and pancreatic. The cfDNA methylation multicancer early detection technology is aided by machine learning and received FDA breakthrough device designation in January 2023. Chip Diagnostics, USA Developer of exosome-based diagnostics making early cancer diagnosis possible. Their pancreatic cancer test utilizes biomarkers, exosome-based miRNA, cfDNA, and CA19-9 proteins, and is in clinical development. Their liver cancer test, is currently under preclinical development. ClearNote Health, USA The company's current focus is on pancreatic cancer with their Avantect pancreatic cancer test. The test utilizes an epigenomics approach and measures levels of the biomarker 5-hydroxymethylcytosine to detect pancreatic cancer. They are also developing a targeted multi-cancer test.